Psychedelics: the pathway to implementation in the European healthcare systems
The integration of psychedelic therapies into European healthcare is a nuanced process that involves not only obtaining European Medicines Agency (EMA) approval but also successfully navigating Health Technology Assessment (HTA) evaluations across member states. After EMA approval, which focuses on...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
January 2026
|
| In: |
European neuropsychopharmacology
Year: 2026, Volume: 102, Pages: 41-48 |
| ISSN: | 1873-7862 |
| DOI: | 10.1016/j.euroneuro.2025.11.007 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.euroneuro.2025.11.007 Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S0924977X25007862 
|
| Author Notes: | Gerhard Gründer, Lea J. Mertens, Moritz Spangemacher, Andreas Meyer-Lindenberg, Henrik Jungaberle |
| Summary: | The integration of psychedelic therapies into European healthcare is a nuanced process that involves not only obtaining European Medicines Agency (EMA) approval but also successfully navigating Health Technology Assessment (HTA) evaluations across member states. After EMA approval, which focuses on the safety, efficacy, and quality of the therapeutic, HTA agencies assess these therapies for their “added therapeutic value,” considering factors like cost-effectiveness, clinical outcomes, and overall societal impact. Each country's HTA, including the UK’s National Institute for Health and Care Excellence (NICE), Germany’s Institute for Quality and Efficiency in Health Care (IQWiG), and France’s Haute Autorité de Santé (HAS), plays a pivotal role in determining reimbursement and access to these treatments. An added challenge is that HTA bodies in Europe often require active comparator studies rather than just placebo controls to establish a treatment’s advantage over existing standard of care - a particular hurdle for psychedelic-assisted therapies, where controlled trials against active comparators are almost completely lacking. Furthermore, psychedelics are typically integrated with psychotherapy, adding complexity to HTA evaluations, as few frameworks currently assess the value of combination therapies within healthcare systems. Creating a standardized HTA approach or a unified European guideline for such novel treatments could promote equitable access across countries, helping to overcome the discrepancies in market access and patient reach across Europe. |
|---|---|
| Item Description: | Online verfügbar: 3. Dezember 2025, Artikelversion: 3. Dezember 2025 Gesehen am 26.01.2026 |
| Physical Description: | Online Resource |
| ISSN: | 1873-7862 |
| DOI: | 10.1016/j.euroneuro.2025.11.007 |